Clinical Trials
15 trialsNCT01251861 2026-05-29
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07393867 2026-05-29
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07593079 2026-05-18
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT00544830 2026-05-15
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07455903 2026-05-13
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Recruiting
NCT03650894 2026-04-13
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Providence Health & Services
Phase 2 Active not recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06365788 2026-04-01
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT05327647 2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT07117851 2025-08-12
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Fudan University
Phase 2 Recruiting